Skip to main content
. 2013 Sep 3;53(1):1–16. doi: 10.1007/s40262-013-0100-7

Fig. 2.

Fig. 2

Summary of absorption, distribution, metabolism, and elimination of rivaroxaban [3, 16, 36]. All numbers given are approximate. BCRP breast cancer resistance protein, CL sys systemic (plasma) clearance, CL R renal clearance (via active secretion CLRS and glomerular filtration CLRF), CYP3A4 cytochrome P450 3A4, CYP2J2 cytochrome P450 2J2, F abs absolute bioavailability, P-gp P-glycoprotein, V ss volume of distribution at steady-state